19:42:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020


ListaMERK Equities
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2021-10-19 23:58:13
"Company"), a clinical stage precision medicine company utilising Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announced
changes to the management team.

Dr Rafiq Hasan has decided to step down as CEO of the Company to pursue other
business interests. Before joining EXACT-Tx, Dr Hasan spent more than 15 years
in Ophthalmology and is now looking to move back into the sector. During his
tenure at EXACT-Tx, Dr Hasan has established a strong management team and
prepared the company to restart recruitment into the Phase I ACTIVATE study in
the coming months.

Dominic Moreland, currently CFO will assume the additional Interim CEO position
and Dr Masha Strømme will assume the position of Executive Chair during the
recruitment process for a successor to Dr Hasan. Dominic and Masha will work
with Dr Hilary McElwaine-Johnn (CMO of EXACT-Tx) to ensure an orderly transition
of leadership and smooth continuation of pre-clinical and clinical development

Dr Masha Strømme, Chair of the Board of Directors of EXACT-Tx commented "I would
like to thank Rafiq for his dedicated work for the Company and wish him every
success in the future".

About ACT®
ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.

ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.

The initial focus of the company is oncology, however the ACT® platform has
potential across several therapeutic areas (infectious diseases, CNS,
immunotherapy) and product classes.

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

For more information contact:

Dominic Moreland
CFO and Interim CEO